Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Reuters: "Danaher Corp (DHR), which jumped 11.5% as its molecular diagnostics company Cepheid received the U.S. Food and Drug Administration's approval for the first rapid coronavirus diagnostic test."
SA: "Danaher's Cepheid gets authorization for quicker Covid-19 test"
* The U.S. Food and Drug Administration issues the first emergency use authorization for a point-of-care Covid-19 diagnostic for the Cepheid Xpert Xpress SARS-CoV 2 test.
* Cepheid is part of Danaher (NYSE:DHR).
* The test will provide results within hours, rather than days like existing tests, said HHS Secretary Alex Azar.
* Cepheid said the test has been designed to operate on any of its more than 23,000 automated GeneXpert Systems worldwide, with a detection time of ~45 minutes.
* The company plans to roll out the new test by March 30, the FDA said, while Cepheid said the test will begin shipping next week." more...
https://seekingalpha.com/news/3554024-danahers-cepheid-gets-authorization-for-quicker-covidminus-19-test
The question is: will the current market allow this to explode on Monday?
And/or...
Will this gap up at the open of premarket and not allow anyone to jump in for the ride?
Thank you Very much for that excellent confirmation Summary! It is great news and much appreciated!
"FDA Approves First Bedside Covid-19 Test by Danaher’s Cepheid"
"March 21, 2020, 1:08 PM CDT"
"A Covid-19 test can deliver results in less than an hour has been approved under an FDA emergency authorization, marking the first test that clinicians can use at the bedside.
Testing shortages have been an ongoing challenge in the U.S. response to curb the pandemic. The White House has promised testing will ramp up as more private companies come on board.
Public health and clinical labs have run more than 195,000 tests to date, but that doesn’t include hospital laboratories running their own test, Brett Giroir, assistant secretary for health at the U.S. Department of Health and Human Services, said during a White House briefing Saturday.
Cepheid, a Silicon Valley molecular diagnostics company that’s a unit of Danaher Corp., announced Saturday it received an emergency authorization from the U.S. Food and Drug Administration to use the test, making it the 13th Covid-19 test the agency has allowed on the market as long as the public health emergency exists.
But it’s the first one that can be used at the point of care, meaning providers don’t have to send patient samples to a separate lab to be processed and then come back to the hospital or provider’s office. Cepheid said it expects to start shipping tests next week.
“An accurate test delivered close to the patient can be transformative—and help alleviate the pressure that the emergence of the 2019-nCoV outbreak has put on healthcare facilities that need to properly allocate their respiratory isolation resources,” David Persing, Cepheid chief medical and technology officer."
https://www.bloomberg.com/news/articles/2020-03-21/fda-approves-first-bedside-covid-19-test-by-cepheid
Rusty8350–Thank you very much for confirming that and also for the heads up about Biomerieux! I appreciate both much!
Yes - this is the company that owns Cepheid and their testing platform genexpert is in almost any hospital and WILL be what most hospitals use for the testing for covid19 in house. Biomerieux is another company that has the bio fire test that will likely be approved soon as well. Almost everyone uses that platform as well and it would be even more likely to be used as they have a panel test that could test for this strain of Coronavirus as well as many other viruses that could cause illnesses all at once.
Did DHR just get approval by FDA this weekend for a novel effective 45 minute corona virus detection kit please? I read that Cepheid Co got FDA approval but that they were bought by DHR a few years back! Will DHR soar Monday am? Do you have knowledge of what I mentioned please? Thank you much!
DHR has performed beautifully. Still outperforming the broad market even since CV hit. Dividend looks solid for now.
Smart guy and a pos company
How’s that record high working bud
40 dollars away
Thanks for doing the research on this...we shall see!
"... FDA said in a statement that state and local public health labs will be able to test up to 75,000 people by the end of the week. That spokesperson added that a commercial manufacturer, IDT is producing additional CDC tests and expects to have shipped test kits capable of about 1 million tests to academic, healthcare and commercial labs by the week's end."
https://www.cnn.com/2020/03/03/politics/pence-coronavirus-any-american-tested/index.html
Good find, perhaps: "IDT manufactures products used in diagnostic tests for many forms of cancer and most inherited and infectious diseases. In addition, researchers involved with the National Institutes of Health Human Microbiome Project are using our products to further the understanding of human microbiota diversity."
https://www.danaher.com/our-businesses/life-sciences/integrated-dna-technologies-idt
I didn't hear VP Pence but I'll do some research
Anyone know if the acquisition of IDT (integrated DNA technologies)back in 2018 by this company. Is this the same IDT company who VP Mike Pence just mentioned in the press conference as the company providing the Covid 19 test kits?
Pos company anyways
BEAST MODE EVER MORE FOR YEARS TO COME ..
H2O is the most important element on planet ..
Oh my gosh ...
DHR WILL BE A GREAT SHORT ON ANY MARKET WEAKNESS
Despite the acquisition of GE Biopharma the stock performance this year is hard to quantify, it does seem that it has ran a little too far to fast and needs a healthy pullback. We assume that when the selling does start it could snowball into quite a drop as large profits are banked and sellers find it hard to offload their portfolio. We will be looking at this as a short when the indicators become more oversld
"Danaher (NYSE:DHR) declares $0.17/share quarterly dividend, 6.3% increase from prior dividend of $0.16."
My Lord! $123.00
Make that $108, not $208.
Record high for Danaher at $208. Anyone else own this longtime winner?
Can anyone explain how you beat expectations clearly. Then stock goes south 15%. The fundamentals and my DD sees growth not reversal
DHR 4Q17 results:
https://finance.yahoo.com/news/danaher-reports-fourth-quarter-full-110000992.html
DHR logged double-digit growth in emerging markets for 4Q17 and full-year 2017.
Inasmuch as DHF pre-announced strong 4Q17 results at the JPM conference in mid-January (#msg-137540935), the selloff today is not surprising.
DHR +3% to new high on 4Q17 earnings above prior guidance:
https://finance.yahoo.com/news/danaher-ceo-financial-performance-010500323.html
This PR was released in conjunction with the JPM webcast.
DHR write-up in TMF echoes stuff previously posted on iHub: #msg-132822622.
FDA approves Beckman Coulter test for leukemia/lymphoma:
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm565321.htm
DHR’s Sciex gets China approval for high-end mass-spec/liquid-chrom device:
#msg-132602984
DHR CC slides from GS webcast (6/14/17):
http://investors.danaher.com/image/2017+Danaher+at+Goldman+Sachs+Healthcare.pdf
DHR 1Q17 CC slides:
http://investors.danaher.com/image/1Q2017+Danaher+Earnings+Presentation.pdf
Bought new position today at 86.41-86.51.
DHR sells €600M ($675M) of 10-year bonds at 1.2%:
https://finance.yahoo.com/news/danaher-announces-pricing-euro-denominated-121100751.html
They also sold €250M of 5-year floating-rate notes. The proceeds will be used, in part, to repay maturing debt securities.
Better Than The Berkshire Hathaway? Danaher's Value (7/13/15)
http://seekingalpha.com/article/3319095-better-than-the-berkshire-hathaway-danahers-value
Danaher Announces Preliminary Results of Split-Off Exchange Offer in Connection with NetScout Transaction; Completes Merger (7/14/15)
-- Danaher completed the merger of its Communications businesses (including Tektronix Communications, Arbor Networks and parts of Fluke Networks) with NetScout in a tax-free transaction to create a premier global provider of network management solutions for carrier and enterprise customers.
WASHINGTON, July 14, 2015 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today the preliminary results of its exchange offer for Danaher common stock in connection with the previously announced separation of Danaher's Communications business and the merger of Potomac Holding LLC, the Danaher subsidiary holding its Communications business, with a subsidiary of NetScout Systems, Inc. (NASDAQ: NTCT). Danaher has accepted shares of Danaher common stock tendered in the exchange offer, subject to proration, and the merger has closed.
In the exchange offer, Danaher shareholders had the option to exchange some, none or all of their shares of Danaher common stock for Potomac Holding LLC common units, subject to proration. As a result of the closing of the merger, each Potomac Holding LLC common unit has been automatically converted into the right to receive one share of NetScout common stock. As a result, Danaher shareholders who tendered their shares of Danaher common stock as part of the exchange offer will receive approximately 2.4000 shares of NetScout common stock for each share of Danaher common stock tendered and accepted for exchange.
Exchange Offer Results
Pursuant to the exchange offer, which expired at midnight, New York City time, on July 13, 2015, and based on a preliminary count by the exchange agent, a total of approximately 31,249,037 shares of Danaher common stock were validly tendered and not properly withdrawn prior to the expiration of the exchange offer, including 12,556,040 shares tendered pursuant to guaranteed delivery procedures. The total number of shares tendered includes an estimated 175,603 shares of Danaher common stock tendered by odd-lot shareholders (excluding certain plan participants in Danaher savings plans) not subject to proration. Danaher will exchange a total of 26,041,666 shares of Danaher common stock in the exchange offer.
Based on the total number of shares of Danaher common stock reported to be tendered and not properly withdrawn prior to the expiration of the exchange offer, including shares tendered pursuant to guaranteed delivery procedures, the exchange offer was oversubscribed by approximately 5,207,371 shares, resulting in a preliminary proration factor of approximately 83.24 percent.
Danaher will not be able to determine the final proration factor until the end of the exchange offer's guaranteed delivery period at 5:00 p.m., New York City time, on July 16, 2015. Danaher will publicly announce the final proration factor, which may be different from today's preliminary estimate, after it has been determined.
Because more than 26,041,666 shares of Danaher common stock were tendered, following the closing of the merger, all Potomac Holding LLC common units owned by Danaher have been deposited with the exchange agent for distribution in the exchange offer.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands have unparalleled leadership positions in some of the most demanding and attractive industries, including health care, environmental and industrial. The company's globally diverse team of 71,000 associates is united by a common culture and operating system, the Danaher Business System. In 2014, Danaher generated $19.9 billion in revenue and its market capitalization exceeded $60 billion. For more information please visit www.danaher.com.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical, including statements regarding the expected effects of the proposed distribution of the Communications business to Danaher stockholders and the combination of such business with NetScout (the "Transaction"), the anticipated timing and terms of the Transaction and any other statements regarding events or developments that Danaher believes or anticipates will or may occur in the future, are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These risks and uncertainties include, among other things, the parties' ability to complete the Transaction on the anticipated terms and schedule, including the anticipated tax treatment for the Transaction, the risk that the Transaction will harm Danaher's business, and the risk of deterioration of or instability in the business performance of the Communications business or NetScout, of their respective served markets or in the general economy.
Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in Danaher's SEC filings, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. These forward-looking statements speak only as of the date of this release and Danaher assumes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
ADDITIONAL INFORMATION
This communication does not constitute an offer to buy, or a solicitation of an offer to sell, any securities of NetScout, Danaher's Communications business or Danaher. In connection with the Transaction, Potomac Holding LLC has filed with the Securities and Exchange Commission ("SEC") a registration statement on Form S-4 and Form S-1 in connection with its separation from Danaher, and NetScout has filed with the SEC a registration statement on Form S-4, each of which includes a prospectus. Investors and security holders are urged to read the registration statements, the prospectus and any other relevant documents, because they contain important information about NetScout, the Communications business of Danaher and the Transaction. The registration statements, the prospectus and other relevant documents relating to the Transaction can be obtained free of charge from the SEC's website at www.sec.gov. These documents can also be obtained free of charge from Danaher's website at investors.danaher.com/netscout or upon written request to NetScout Systems, Inc., Investor Relations, 310 Littleton Road Westford, MA 01886 or by calling 978-614-4279.
TENDER OFFER DOCUMENTS
On May 14, 2015, Danaher filed with the SEC a tender offer statement on Schedule TO regarding the exchange offer for the split-off of the Communications business as part of the proposed Transaction. Investors and security holders are urged to read the tender offer statement (as updated and amended) because it contains important information about the Transaction.
Investors and security holders may obtain a free copy of the tender offer statement and other documents filed by Danaher with the SEC on the SEC's web site at www.sec.gov. The tender offer statement and other documents may also be obtained free of charge from Danaher's website at investors.danaher.com/netscout.
SOURCE Danaher Corporation
http://www.prnewswire.com/news-releases/danaher-announces-preliminary-results-of-split-off-exchange-offer-in-connection-with-netscout-transaction-completes-merger-300112864.html
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
121
|
Created
|
04/19/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |